About Ovarian Cancer

Ovarian cancer is rare but deadly1

Ovarian cancer statistics
Ovarian cancer statistics
Bottom Shadow

A Diagnosis of Advanced-Stage Ovarian Cancer Often Leads to Poor Prognosis2

Stage at diagnosis chart
Stage at diagnosis chart
5 year survival by stage chart
5 year survival by stage chart

Despite optimal surgical outcomes and high response rates to 1L platinum-based chemotherapy, the outlook in advanced ovarian cancer remains poor3,4

85% recurrence rate in advanced ovarian cancer after initial treatment
85% recurrence rate in advanced ovarian cancer after initial treatment

Without maintenance, PFS shortens with each recurrence5

Ovarian cancer recurrence bar chart
Ovarian cancer recurrence bar chart
Bottom Shadow

There is a need for a maintenance therapy that3,6-8:

need-for-maintenance-therapy

PROLONGS
progression-free survival

need-for-maintenance-therapy-1

EXTENDS
PARP inhibitor therapy to more
women9-11

need-for-maintenance-therapy-2

Offers
CONVENIENT
once-daily, oral dosing

1L, first-line; BRCA, breast cancer susceptibility gene; CI, confidence interval; PARP, poly (ADP-ribose) polymerase; PFS, progression-free survival.

Efficacy Data

View efficacy data for
all indications

Study Design

See the PRIMA clinical
trial design

References: 1. American Cancer Society. Cancer Facts & Figures 2019. Atlanta, GA: American Cancer Society; 2019. 2. SEER Cancer Stat Facts: ovarian cancer. National Cancer Institute website. https://seer.cancer.gov/statfacts/html/ovary.html. Accessed March 2, 2021. 3. Lorusso D, Mancini M, Di Rocco R, Fontanelli R, Raspagliesi F. The role of secondary surgery in recurrent ovarian cancer. Int J Surg Oncol. 2012;2012:613980. Doi:10.1155/2012/613980. 4. Howlader N, Noone AM, Krapcho M, et al, eds. SEER Cancer Statistics Review. 1975-2016. Bethesda, MD: National Cancer Institute. https://seer.cancer.gov/csr/1975_2016/, based on November 2019 SEER data submission, posted to the SEER website, April 2020. Accessed March 2, 2021. 5. Hanker LC, Loibl S, Burchardi N, et al. The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy. Ann Oncol. 2012;23(10):‍2605-2612. 6. Matulonis UA. Management of newly diagnosed or recurrent ovarian cancer. Clin Adv Hematol Oncol. 2018;16(6):426-437. 7. Banerjee SN, Lord CJ. First-line PARP inhibition in ovarian cancer — standard of care for all? Nat Rev Clin Oncol. 2020;17(3):136-137. 8. Krikorian SA, Shamim K. Adherence issues for oral antineoplastics: a focus on prevention and management of side effects related to targeted therapies. Am J Lifestyle Med. 2013;7(3):206-222. 9. ZEJULA (niraparib). Prescribing Information. GlaxoSmithKline; 2021. 10. Lynparza (olaparib). Prescribing Information. AstraZeneca Pharmaceuticals LP; 2020. 11. Rubraca (rucaparib). Prescribing Information. Clovis Oncology, Inc; 2020.